Gallia Levy
Dr Levy’s passion for coagulation started with her PhD dissertation research in the laboratory of Dr David Ginsburg at the University of Michigan. She studied the genetic basis for the variability of VWD and cloned the ADAMTS13 gene that is the genetic basis for thrombotic thrombocytopenic purpura (TTP). Dr. Levy completed her medical and doctoral training at the University of Michigan, followed by internal medicine at Stanford University and hematology fellowship at the University of California, San Francisco (UCSF). She is board-certified in hematology and previously served as adjunct clinical faculty at UCSF on the hematology consultation service.
Dr Levy first joined Genentech in 2009, where she worked in both early and late development on several products. She later moved to Portola Pharmaceuticals, where she led the clinical development program for andexanet alfa, a FX inhibitor antidote. Dr Levy returned to Roche/Genentech in 2014 to lead the clinical development program for emicizumab (Hemlibra). Under her leadership, Hemlibra has gone from proof of concept to approval in adults and children with hemophilia A of all ages with and without FVIII inhibitors in less than 5 years. Dr. Levy is now a Group Medical Director at Genentech, leading the non-malignant hematology late stage clinical development group.